Yomiuri: Fujirebio Submits Blood Test Kit for Early Alzheimer's Detection for Approval to Japan Health Ministry

Dow Jones

Nov 26

By Nozomi Suzuki / Yomiuri Shimbun Staff Writer

Japanese testing reagent maker Fujirebio Inc. announced on Tuesday that it has applied to the Japanese Health, Labor and Welfare Ministry for approval to manufacture and sell a blood test kit to assist in diagnosing Alzheimer's disease. The kit is expected to reduce the burden on patients compared to conventional tests, and lead to earlier diagnosis.

Alzheimer's disease is thought to occur when abnormal proteins called "amyloid beta" and "tau" accumulate in the brain, damaging nerve cells and leading to cognitive decline. The test kit measures the concentration of these proteins in plasma, according to the company.

Currently, the procedures for diagnosis include expensive imaging tests like "amyloid PET" scans and invasive lumbar puncture procedures to test cerebrospinal fluid. If approved, Fujirebio's test would only require a blood draw, thus reducing the burden on patients and believed to make testing more accessible.

----

This article is from The Yomiuri Shimbun. Neither Dow Jones Newswires, MarketWatch, Barron's nor The Wall Street Journal were involved in the creation of this content.

YDN-M0000160789-1

(END) Dow Jones Newswires

November 26, 2025 02:36 ET (07:36 GMT)

Copyright (c) 2025 The Yomiuri Shimbun

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2586239944"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2586239944\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2586239944?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-26 15:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2586239944","market":"nz","top_or_hot":-1,"title":"Yomiuri: Fujirebio Submits Blood Test Kit for Early Alzheimer's Detection for Approval to Japan Health Ministry","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Nozomi Suzuki / Yomiuri Shimbun Staff Writer \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Japanese testing reagent maker Fujirebio Inc. announced on Tuesday that it has applied to the Japanese Health, Labor and Welfare Ministry for approval to manufacture and sell a blood test kit to assist in diagnosing Alzheimer's disease. The kit is expected to reduce the burden on patients compared to conventional tests, and lead to earlier diagnosis. \n</p>\n<p>\n  Alzheimer's disease is thought to occur when abnormal proteins called \"amyloid beta\" and \"tau\" accumulate in the brain, damaging nerve cells and leading to cognitive decline. The test kit measures the concentration of these proteins in plasma, according to the company. \n</p>\n<p>\n  Currently, the procedures for diagnosis include expensive imaging tests like \"amyloid PET\" scans and invasive lumbar puncture procedures to test cerebrospinal fluid. If approved, Fujirebio's test would only require a blood draw, thus reducing the burden on patients and believed to make testing more accessible. \n</p>\n<p>\n    ---- \n</p>\n<p>\n  This article is from The Yomiuri Shimbun. Neither Dow Jones Newswires, MarketWatch, Barron's nor The Wall Street Journal were involved in the creation of this content. \n</p>\n<p>\n  YDN-M0000160789-1 \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 26, 2025 02:36 ET (07:36 GMT)\n</p>\n<p>\n  Copyright (c) 2025 The Yomiuri Shimbun\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Yomiuri: Fujirebio Submits Blood Test Kit for Early Alzheimer's Detection for Approval to Japan Health Ministry</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nYomiuri: Fujirebio Submits Blood Test Kit for Early Alzheimer's Detection for Approval to Japan Health Ministry\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-11-26 15:36</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Nozomi Suzuki / Yomiuri Shimbun Staff Writer \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Japanese testing reagent maker Fujirebio Inc. announced on Tuesday that it has applied to the Japanese Health, Labor and Welfare Ministry for approval to manufacture and sell a blood test kit to assist in diagnosing Alzheimer's disease. The kit is expected to reduce the burden on patients compared to conventional tests, and lead to earlier diagnosis. \n</p>\n<p>\n  Alzheimer's disease is thought to occur when abnormal proteins called \"amyloid beta\" and \"tau\" accumulate in the brain, damaging nerve cells and leading to cognitive decline. The test kit measures the concentration of these proteins in plasma, according to the company. \n</p>\n<p>\n  Currently, the procedures for diagnosis include expensive imaging tests like \"amyloid PET\" scans and invasive lumbar puncture procedures to test cerebrospinal fluid. If approved, Fujirebio's test would only require a blood draw, thus reducing the burden on patients and believed to make testing more accessible. \n</p>\n<p>\n    ---- \n</p>\n<p>\n  This article is from The Yomiuri Shimbun. Neither Dow Jones Newswires, MarketWatch, Barron's nor The Wall Street Journal were involved in the creation of this content. \n</p>\n<p>\n  YDN-M0000160789-1 \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 26, 2025 02:36 ET (07:36 GMT)\n</p>\n<p>\n  Copyright (c) 2025 The Yomiuri Shimbun\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK6031","symbol_name":"特种化学制品","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2586239944","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2586239944","pubTimestamp":1764142560,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Japanese testing reagent maker Fujirebio Inc. announced on Tuesday that it has applied to the Japanese Health, Labor and Welfare Ministry for approval to manufacture and sell a blood test kit to assist in diagnosing Alzheimer's disease. The kit is expected to reduce the burden on patients compared to conventional tests, and lead to earlier diagnosis.Alzheimer's disease is thought to occur when abnormal proteins called \"amyloid beta\" and \"tau\" accumulate in the brain, damaging nerve cells and leading to cognitive decline. The test kit measures the concentration of these proteins in plasma, according to the company.Currently, the procedures for diagnosis include expensive imaging tests like \"amyloid PET\" scans and invasive lumbar puncture procedures to test cerebrospinal fluid. If approved, Fujirebio's test would only require a blood draw, thus reducing the burden on patients and believed to make testing more accessible.This article is from The Yomiuri Shimbun. Neither Dow Jones Newswire","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK6031":"特种化学制品","SG9999001069.SGD":"UOB UNITED ASIA PACIFIC GROWTH (SGD) ACC","BK6102":"燃气公用事业","SG9999003461.SGD":"United Asia Pacific Infrastructure SGD","A7RU.SI":"吉宝基础设施信托","BK6501":"化工股","SG9999004360.SGD":"Nikko AM Shenton Thrift Fund SGD","SG9999002950.SGD":"United Asian Growth Opportunities SGD","SG9999003826.SGD":"日兴资管新加坡股息基金 SGD"},"translate_title":"读卖新闻：Fujirebio向日本厚生省提交用于早期阿尔茨海默病检测的血液检测试剂盒以供批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"A7RU.SI":1.5},"content_text":"By Nozomi Suzuki / Yomiuri Shimbun Staff Writer \n\n\n \n\n\n  Japanese testing reagent maker Fujirebio Inc. announced on Tuesday that it has applied to the Japanese Health, Labor and Welfare Ministry for approval to manufacture and sell a blood test kit to assist in diagnosing Alzheimer's disease. The kit is expected to reduce the burden on patients compared to conventional tests, and lead to earlier diagnosis. \n\n\n  Alzheimer's disease is thought to occur when abnormal proteins called \"amyloid beta\" and \"tau\" accumulate in the brain, damaging nerve cells and leading to cognitive decline. The test kit measures the concentration of these proteins in plasma, according to the company. \n\n\n  Currently, the procedures for diagnosis include expensive imaging tests like \"amyloid PET\" scans and invasive lumbar puncture procedures to test cerebrospinal fluid. If approved, Fujirebio's test would only require a blood draw, thus reducing the burden on patients and believed to make testing more accessible. \n\n\n    ---- \n\n\n  This article is from The Yomiuri Shimbun. Neither Dow Jones Newswires, MarketWatch, Barron's nor The Wall Street Journal were involved in the creation of this content. \n\n\n  YDN-M0000160789-1 \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 26, 2025 02:36 ET (07:36 GMT)\n\n\n  Copyright (c) 2025 The Yomiuri Shimbun","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}